Advertisement

Polypharmacy in Hospice and Palliative Care

  • Angela Yeh
    Correspondence
    Corresponding author. Department of Internal Medicine, Division of Geriatrics, University of California, Los Angeles, 1328 16th Street, Second Floor Santa Monica, CA 90404, USA.
    Affiliations
    Department of Internal Medicine, Division of Geriatrics, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA

    Department of Internal Medicine, Hospice and Palliative Medicine Program, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA
    Search for articles by this author
  • Amy Z. Sun
    Affiliations
    Combined Geriatrics and Palliative Care, Department of Internal Medicine, Division of Geriatrics, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA

    Combined Geriatrics and Palliative Care, Department of Internal Medicine, Hospice and Palliative Medicine Program, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA
    Search for articles by this author
  • Helen Chernicoff
    Affiliations
    Combined Geriatrics and Palliative Care, Department of Internal Medicine, Division of Geriatrics, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA

    Combined Geriatrics and Palliative Care, Department of Internal Medicine, Hospice and Palliative Medicine Program, University of California, Los Angeles, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095, USA
    Search for articles by this author
Published:September 13, 2022DOI:https://doi.org/10.1016/j.cger.2022.05.009

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schenker Y.
        • Park S.Y.
        • Jeong K.
        • et al.
        Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness.
        J Gen Intern Med. 2019; 34: 559-566
        • Holmes H.M.
        Rational prescribing for patients with a reduced life expectancy.
        Clin Pharmacol Ther. 2009; 85: 103-107
      1. NHPCO. National Hospice and Palliative Care Organization Hospice Medicine Deprescribing Toolkit. 2020: 1-32.

        • Reeve E.
        • Farrell B.
        • Thompson W.
        • et al.
        Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.
        Med J Aust. 2019; 210: 174-179
        • Yourman L.C.
        • Cenzer M.A.
        • Boscardin W.J.
        Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 Years. A meta-analysis.
        JAMA Intern Med. 2021; 181: 179-185
        • Wanner C.
        • Krane V.
        • Marz W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Fellstrom B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • et al.
        • for the AURORA Study Group
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Stroes E.S.
        • Thompson P.D.
        • Corsini A.
        • et al.
        Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus Panel statement on assessment, aetiology and management.
        Eur Heart J. 2015; 36: 1012-1022
        • Thompson P.D.
        • Panza G.
        • Zaleski A.
        • et al.
        Statin-associated side effects.
        J Am Coll Cardiol. 2016; 67: 2395-2410
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Navarese E.P.
        • Buffon A.
        • Andreotti F.
        • et al.
        Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.
        Am J Cardiol. 2013; 111: 1123-1130
        • Kutner J.S.
        • Blatchford P.J.
        • Taylor Jr., D.H.
        • et al.
        Safety and benefit of discontinuing statin therapy in the setting of advanced, life limiting illness: a randomized clinical trial.
        JAMA Intern Med. 2015; 175: 691-700
        • Lee S.J.
        • Jacobson M.A.
        • Johnston C.B.
        Improving diabetes care for hospice patients.
        Am J Hosp Palliat Care. 2016; 33: 517-519
        • Petrillo L.A.
        • Gan S.
        • Jing B.
        • et al.
        Hypoglycemia in hospice patients with type 2 diabetes in a national sample of nursing homes.
        JAMA Intern Med. 2018; 178: 713-715
        • Wang J.
        • Geiss L.S.
        • Williams D.E.
        • et al.
        Trends in emergency department visit rates for hypoglycemia and hyperglycemic crisis among adults with diabetes, United States, 2006-2011.
        PLoS One. 2015; 10: e0134917
      2. Deprescribing.org. Guidelines and algorithms: antihyperglycemics deprescribing algorithm. 2018: 1-2.
        (Available at:) (Accessed December 20, 2021)
        • Munshi M.N.
        • Florez H.
        • Huang E.S.
        • et al.
        Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American diabetes association.
        Diabetes Care. 2016; 39: 308-318
        • American Diabetes Association
        12. Older adults: Standards of medical Care in diabetes-2020.
        Diabetes Care. 2020; 43: S152-S162https://doi.org/10.2337/dc20-S012
        • Jeffreys E.
        • Rosielle D.A.
        Fast facts and concepts #258: diabetes management at end-of-life. Reviewed september 2015.
        (Available at:) (Accessed August 24, 2020)
        • Angelo M.
        • Ruchalski C.
        • Sproge B.J.
        An approach to diabetes mellitus in hospice and palliative medicine.
        J Palliat Med. 2011; 14: 83-87
        • Scheufler J.M.
        • Prince-Paul M.
        The diabetic hospice patient: incorporating evidence and medications into goals of care.
        J Hosp Palliat Nurs. 2011; 13 (Available at:): 356-365
        • Thompson J.
        Deprescribing in palliative care.
        Clin Med (Lond). 2019; 19: 311-314
        • Pasierski T.
        Modification of cardiovascular pharmacotherapy in palliative care patients with cancer: a narrative review.
        Pol Arch Intern Med. 2017; 127: 687-693
        • Pasina L.
        • Recchia A.
        • Agosti P.
        • et al.
        Prevalence of preventive and symptomatic drug treatments in hospice care: an Italian observational study.
        Am J Hosp Palliat Care. 2019; 36: 216-221
        • Cho-Reyes S.
        • Celli B.R.
        • Dembek C.
        • et al.
        Inhalation technique errors with metered-dose inhalers among patients with obstructive lung diseases: a systematic review and meta-analysis of U.S. Studies.
        Chronic Obstr Pulm Dis. 2019; 6: 267-280
        • Van Beerendonk I.
        • Mesters I.
        • Mudde A.N.
        • et al.
        Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device.
        J Asthma. 1998; 35: 273-279
        • Russell S.J.F.
        • Russell R.E.K.
        Challenges in end-of-life communication in COPD.
        Breathe. 2007; 4 (Available at:): 133-139
        • Protus B.
        • Kimbrel J.
        • Grauer P.
        Palliative care consultant: guidelines for effective management of symptoms.
        4th edition. HospiScript Services, Montgomery (AL)2015: 225-229
        • Reimer C.
        Safety of long-term PPI therapy.
        Best Pract Res Clin Gastroenterol. 2013; 27: 443-454
        • Farrell B.
        • Pottie K.
        • Thompson W.
        • et al.
        Deprescribing proton pump inhibitors: evidence-based clinical practice guideline.
        Can Fam Physician May. 2017; 63: 354-364
        • Pruskowski J.
        Fast facts and concepts #321 deprescribing. Palliative care network of Wisconsin.
        (Available at:) (Accessed December 20, 2021)
        • Lindsay J.
        • Dooley M.
        • Martin J.
        • et al.
        The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline.
        Support Care Cancer. 2015; 23: 71-78
        • Lavan A.H.
        • Gallagher P.
        • Parsons C.
        • et al.
        STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation.
        Age Ageing. 2017; 46: 600-607